New Femur Fracture Study Reinforces Earlier Findings Linking Osteoporosis Medications to Atypical Femur Fractures
On May 5, 2011, the New England Journal of Medicine published the findings of a Swedish study, which concluded that bisphosphonates, such as Fosamax, increase a patient’s risk for sustaining an atypical femur fracture. Lead researcher Dr. Per Aspenberg, a professor of orthopedics at Linkoping University, stated, “Our data demonstrates beyond a doubt that there is a strong connection between the atypical fracture of the femoral shaft and it is so strong one could argue that it is causative.” The lawyers at Bernstein Liebhard LLP are currently investigating claims against the manufacturers of these bone drugs, and are offering free and confidential legal consultations to individuals who took these bone drugs and fractured their femoral bone.
Recently, Fosamax and similar medications have been the subject of increased scrutiny as numerous studies release findings which substantiate that there is, in fact, a link between Fosamax use and atypical femur fractures. Furthermore, this latest study corroborates an October 13, 2010 warning issued by the U.S. Food and Drug Administration (FDA) that bisphosphonates put patients at risk for atypical thigh bone (femur) fractures. In addition to issuing that warning, the FDA required bisphosphonate manufacturers to change the drugs’ labeling.
Bisphosphonates Increase Femur Fracture Risk
Although prescribed to osteoporotic women to build bone strength and prevent fractures, this latest study found that women have a 47.3 percent relative risk of sustaining an atypical femur fracture while taking bisphosphonates, such as Fosamax. Additionally, the Fosamax study showed “an extremely strong association, a dose-response relationship.” Researchers also concluded that long-term bisphosphonate use further increases the risk of sustaining a femur fracture. However, that risk decreases at a rate of 70 percent each year once a patient stops taking the drug.
Bernstein Liebhard LLP is actively investigating and litigating cases on behalf of clients who have suffered a Fosamax femur fracture. In 2008, the FDA issued its first warning regarding the dangers associated with Fosamax use. Since that time, Bernstein Liebhard LLP has provided a wealth of consumer information concerning the risks associated with Fosamax use on its website, www.consumerinjurylawyers.com. If you or a loved one took Fosamax and sustained a femur fracture, you may be entitled to compensation for medical bills, pain and suffering, lost wages and other injuries.
For more information about filing a Fosamax lawsuit, contact an attorney at Bernstein Liebhard LLP at (877) 779-1414 or at firstname.lastname@example.org.
ATTORNEY ADVERTISING. © 2010 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq. email@example.com (877) 779-1414